Literature DB >> 19190813

Microsatellite (GT)(n) repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions.

Viviana Daidone1, Maria Grazia Cattini, Elena Pontara, Francesca Sartorello, Lisa Gallinaro, Alberto Marotti, Carla Scaroni, Antonio Pagnan, Alessandra Casonato.   

Abstract

Von Willebrand factor (VWF) levels vary considerably in normal individuals, influenced by inherited and acquired modulators. ABO blood group is the major inherited determinant of VWF levels, but a role has also been attributed to the VWF gene promoter, haplotype 1 (-3268G/-2709C/-2661A/-2527G) being associated with higher VWF levels than haplotype 2 (-3268C/-2709T/-2661G/-2527A), and the polymorphic locus (GT)(n) modulating the shear stress-induced activation of the VWF promoter. We characterized the (GT)(n) of the VWF promoter in 394 healthy individuals and assessed whether its variable length influenced VWF levels in normal conditions. (GT)(n) proved highly polymorphic, with alleles from 15 to 24 repeats long. (GT)(21) and (GT)(19) were the most common variants (37.4% and 34.4%, respectively). Short GT repeats (15-19) segregated mainly with haplotype 1, long GT repeats (20-24) with haplotype 2 (p < 0.0001). The number of GT repeats did not correlate with VWF levels, nor did such levels correlate with haplotypes 1 and 2, considered alone or in association with the (GT)(n) locus. We conclude that (GT)(n) and -3268/-2709/-2661/-2527 loci are in strong linkage disequilibrium. This polymorphic region of the VWF promoter does not affect VWF levels under normal conditions, though it might represent an environmentally activable VWF regulation site.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190813

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions.

Authors:  N Hickson; D Hampshire; G Castaman; J Eikenboom; F Rodeghiero; I Peake; A Goodeve
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

Review 2.  Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

Authors:  G Arnaldi; T Mancini; G Tirabassi; L Trementino; M Boscaro
Journal:  J Endocrinol Invest       Date:  2012-04       Impact factor: 4.256

3.  An apparently silent nucleotide substitution (c.7056C>T) in the von Willebrand factor gene is responsible for type 1 von Willebrand disease.

Authors:  Viviana Daidone; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Antonella Bertomoro; Antonio Pagnan; Alessandra Casonato
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

4.  Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile.

Authors:  S Koutroumpi; V Daidone; M T Sartori; M G Cattini; N M Albiger; G Occhi; S Ferasin; A Frigo; F Mantero; A Casonato; C Scaroni
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

5.  Performance related factors are the main determinants of the von Willebrand factor response to exhaustive physical exercise.

Authors:  Janine E van Loon; Michelle A H Sonneveld; Stephan F E Praet; Moniek P M de Maat; Frank W G Leebeek
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.